Head & Neck Cancer (HNSCC) Clinical Trials

About Head & Neck Cancer (HNSCC) trials

Head and neck cancer trials are organized around two questions that often matter more than molecular profile: HPV status (especially in oropharyngeal cancer) and the anatomic site of origin. PD-L1 (CD274) status, usually measured by combined positive score (CPS), gates immunotherapy trials and is foundational because IO is now standard front-line for recurrent/metastatic disease. EGFR has been a long-standing target through anti-EGFR antibody combinations and remains relevant for trials of new EGFR strategies. PIK3CA mutations are common in HNSCC (around 20-30%, more common in HPV-positive disease) and gate trials of PI3K and AKT inhibitors. CDKN2A loss is the most common alteration in HNSCC and contributes to trial stratification rather than direct eligibility. HER2 (ERBB2) amplification or expression is rare but actionable for HER2-targeted ADC trials. MET alterations are uncommon in HNSCC overall but more relevant in salivary gland carcinomas, which are sometimes grouped with HNSCC trials and sometimes separate.

Head and neck cancer trial activity organizes around treatment intent and HPV status. Locally advanced trials test combinations of chemoradiation, often comparing standard cisplatin-based chemoradiation against IO addition, IO substitution, or de-escalation strategies for HPV-positive patients. De-escalation trials in HPV-positive oropharyngeal cancer are a major active area, testing whether reduced radiation dose or substituting IO for chemotherapy can preserve outcomes while reducing long-term toxicity. Recurrent or metastatic first-line trials center on IO combinations; the standard is anti-PD1 plus chemo or anti-PD1 alone for PD-L1 high disease, with trials testing additions and alternatives. Recurrent/metastatic later-line trials test ADCs, novel IO combinations, anti-EGFR strategies, and emerging mechanisms. Salivary gland cancer trials are sometimes embedded as cohorts and sometimes separate, depending on histology. HER2-amplified trials test anti-HER2 ADCs.

HNSCC trial screening typically checks HPV status, anatomic site, and prior immunotherapy exposure. HPV status is foundational, especially for oropharyngeal cancer trials: most de-escalation trials require HPV-positive disease, and some salvage trials specify HPV-negative because of biology differences. Anatomic site (oropharynx, oral cavity, larynx, hypopharynx, nasopharynx) gates many trials, and trials often combine multiple sites or restrict to one. PD-L1 CPS is required for many IO trials, with cutoffs that vary (≥1, ≥20, etc.). Prior immunotherapy exposure: most R/R trials specify whether patients are IO-naïve, IO-pretreated, or post-IO progression specific. Prior platinum chemotherapy and radiation exposure matter for line definition. Smoking history is sometimes captured as a stratification factor for HPV-negative disease. ECOG of 0 or 1 is standard. Adequate swallowing function and weight loss criteria can be specific to head and neck trials because of the anatomical impact of disease and treatment.

Biomarkers tested in Head & Neck Cancer (HNSCC) trials

These are the molecular markers most commonly required or evaluated in Head & Neck Cancer (HNSCC) eligibility criteria. OncoMatch extracts them from each trial's protocol and matches them against your test results.